SCHEMBL2089403

SCHEMBL2089403

CCOc1cc(N)nc(NC(=O)N(C)C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA4 P43681 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
MAPK8 P45983 5/20 0.39
MAPK9 P45984 5/20 0.39
PRKD3 O94806 2/20 0.39
MAP4K4 O95819 1/20 0.39
MAPK10 P53779 1/20 0.39
MAP4K2 Q12851 1/20 0.39
PKN2 Q16513 1/20 0.39
PRKD2 Q9BZL6 1/20 0.39
STK17A Q9UEE5 1/20 0.39
MAP4K1 Q92918 1/20 0.39
ACACB O00763 2/20 0.37
ALDH1A1 P00352 1/20 0.37
ABL1 P00519 1/20 0.36
GCK P35557 1/20 0.36
NPC1 O15118 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2088080 0.84 FBP1 (0.43) ADORA3MAPK8MAPK9ABL1NPC1
SCHEMBL2088251 0.84 ALDH1A1 (0.50) CHRNB2CHRNB4CHRNA3CHRNA4ADORA3
SCHEMBL2087500 0.82 GCK (0.43) CHRNB2CHRNB4CHRNA3CHRNA4ADORA3
SCHEMBL2088216 0.75 FBP1 (0.40) MAP4K1ABL1TP53KDM4E
SCHEMBL2088223 0.73 TSHR (0.48) ALDH1A1NPC1SMN1; SMN2TP53KDM4E
SCHEMBL11446844 0.71 XIAP (0.59) ALDH1A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL9381142 0.68 LMNA (0.67) ALDH1A1NPC1SMN1; SMN2KDM4EMAPT
SCHEMBL27258903 0.68 SMN1; SMN2 (0.45) ADORA3ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2087960 0.67 FBP1 (0.46) ADORA3MAPK8MAPK9NPC1RAB9A
SCHEMBL4321611 0.66 GCK (0.53) GCKMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163778-B2 Pyridines as FBPase inhibitors for treatment of diabetes HOFFMANN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2227452-A2 PYRIDINE COMPOUNDS F. Hoffmann-La Roche AG (CH) 2010-09-15 EP disclosed
WO-2009068468-A2 PYRIDINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 WO disclosed
US-20090143439-A1 NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES HOFFMANN-LA ROCHE, INC. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143439-A1 NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES FBP1, PDXK, G6PC1 CHRNB2 2838/4885CHRNB4 2680/4885CHRNA3 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.